Funds & Grants

Product development partnerships (PDPs) are non-profit organisations that bridge the gap between the need for new treatments for poverty-related diseases and the resources available to develop them, leveraging a mix of public, philanthropic, multilateral, and private sector funding. We aimed to calculate two financial metrics to estimate the return on investments of drugs developed by the PDP Medicines for Malaria Venture (MMV) as a case study.

📢 CARB-X is pleased to share we will be accepting applications for therapeutic, preventative, and diagnostic products as part of our 2026 Funding Round. The full details, including product themes, Target Product Profiles, minimal entry criteria, application timelines, and Frequently Asked Questions will be published soon. 📩 Sign up for the CARB-X newsletter to receive updates: bit.ly/42hkl #AMR #StopSuperBugs #SuperBugs #AntibioticResistance #Medicine #GlobalHealth #ProductDevelopment #Innovation #Biotechnology

Germany's leading applied research organisation, the Fraunhofer Society, is giving its spin-out fund a boost, with a planned capitalisation of €90 million. The fund will also be opened up to the country's other research organisations. The new TT49 fund builds on a previous Fraunhofer Technology Transfer Fund, offering pre-seed funding to spin-outs in all technology fields, except for drug research, which is considered too costly and time-intensive.

A new review of the UK's university spin-out system says the country hugely underinvests in proof-of-concept funding for new ideas emerging from labs, and recommends the creation of a £100 million fund to plug the gap. The analysis, commissioned by the country's main public funder, UK Research and Innovation, comes however at a time of strained science budgets and university finances, which could limit the country's ability to reform its system. The UK's university spin-out scene is generally seen as ahead of that in the EU. The country is second only to the US when it comes to raising money from venture capitalists, for example.

Det kan de både bruge, mens de er her i Danmark, men det giver dem også kompetencer, de kan bruge til at genopbygge Ukraine i fremtiden. Forperson i Danmarks Erhvervsfremmebestyrelse Christian Motz feldt siger: Når der kommer op mod 1.000 ukrainske flygtninge til Danmark hver ene ste måned, giver det utrolig god mening at investere i projekter som dette, hvor endnu flere af dem får en kortere vej hen mod selvforsørgelse, og hvor de får redskaber til at være med til at genopbygge et dynamisk erhvervsliv i Ukraine. Indtil videre har mere end 3.000 ukrainske flygtninge deltaget i projekter, og nu kan vi arbejde videre med de gode erfaringer, når endnu flere ukrainere inviteres med ind i fællesskabet, hvor de samtidig får styrket deres kompetencer." Fakta: • Indsatsen har allerede hjulpet over 1.700 ukrainere med kompe tenceløft til at starte egen virksomhed, mens mere end 1.350 ukra inske flygtninge har udviklet kompetencer gennem en lignende indsats, der også er støttet af bestyrelsen. • Ivækst, der leverer indsatsen, forventer, at yderligere 900 ukrain ske flygtninge vil deltage i projektet med de nye midler, hvoraf 630 forventes at få forbedrede iværksætterkompetencer, som kan anvendes til at starte og drive virksomhed i Danmark eller ved en senere genopbygning af Ukraine."

The European Commission will propose a new pilot instrument to accelerate the time to market of defence technologies in the next month," the annual Science|Business conference heard on February 5. "For the first time, instead of having three or four years from call to conclusion, it will be six to 12 months," said Michalis Ketselidis, senior expert for defence industry and space at the European Commission. The initiative, called Agile, was first announced in the Commission's defence industry roadmap adopted in November 2025. At the time, defence Commissioner Andrius Kubilius said Agile would support single companies "to develop low-cost production in a very rapid manner," as opposed to the European Defence Fund, which supports collaborative projects."

Vi åbner vi nu for Agile Piloting gennem Horizon Europe-projektet UNITE: En kort, praksisnær pilot på et UNITE test-site i en af vores partnerregioner i bl.a. Italien, Grækenland, Skotland, Holland, Spanien og Rumænien. Formålet er enkelt: at teste og validere din løsning i et andet sundhedssystem – i tæt samarbejde med klinikere og fagpersoner på tværs af Europa Piloten skal: 🔹 være praksisnær og afgrænset (ml. Muligheden er for dig, der: ✔️ er kliniker i Region Sjælland ✔️ er tilknyttet en virksomhed som konsulent og/eller indehaver ✔️ har en løsning på minimum TRL-niveau 4 ✔️ kan deltage aktivt i piloten og bidrage til evaluering og læring Der er 4 pladser, som tildeles efter først til mølle-princippet, med forventet opstart i marts/april. Du skal selv finde test-eller læringssted i en ønsket region, så det er en fordel, hvis du allerede har kendskab til samarbejdspartnere i UNTE-regionerne.

INCATE (INCubator for Antibacterial Therapies in Europe), the antimicrobial incubator supporting the advancement of early stage anti-infectives, announced a defining milestone in its institutional journey with the appointment of Dr. Holger Zimmermann as its first Chief Executive Officer (CEO).

CARB-X announced today that it's awarding Chembio Diagnostic Systems $1.8 million to support the development of a rapid, finger stick–based diagnostic test for typhoid fever. The money will help Chembio, of Medford, New York, develop a blood-based point-of-care test, using its proprietary Dual Path Platform, that can detect acute infection caused by Salmonella enterica serovar Typhi based on the presence of immunoglobulin A (IgA) antibodies. Could be good news for lower-income nations A rapid, fingerstick-based test that delivers reliable results at the point of care could significantly improve how typhoid fever is diagnosed in low- and middle-income countries, where access to laboratory infrastructure is often limited," Richard Alm, PhD, interim chief of research & development at CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), said in a press release. "If successful, Chembio's diagnostic capability can support better clinical decision-making, strengthen surveillance and stewardship efforts, and contribute to more effective management of enteric fever in high-burden settings." Since its founding in 2016, CARB-X has funded 122 projects designed to prevent, treat, and diagnose antibiotic-resistant infections."

How to achieve funding for your life science innovation project